Navigation Links
KannaLife Sciences, Inc. Signs Exclusive License Agreement with National Institutes of Health Office of Technology Transfer (NIH-OTT)
Date:7/9/2012

NEW YORK, July 9, 2012 /PRNewswire/ -- KannaLife Sciences, Inc. ("KannaLife") Signs Exclusive License Agreement With National Institutes of Health – Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent 6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent").

The '507 Patent includes among other things, claims directed to a method of treating diseases caused by oxidative stress by administering a therapeutically effective amount of a non-psychoactive cannabinoid that has substantially no binding to the NMDA receptor. Cannabinoids are any of a group of related compounds that include cannabinol and the active constituents of cannabis (marijuana).

Pursuant to the terms of the exclusive license with NIH-OTT, KannaLife intends to move forward with its commercial development plan, and design a novel new drug compound for the treatment of Hepatic Encephalopathy (HE). KannaLife believes its target drug candidate will be comprised of one or more cannabinoid(s) for use and delivery in humans as FDA approved drugs. Currently, in the United States, there are over 1.5 million sufferers of Hepatic Encephalopathy,

Dean Petkanas, Founder and CEO of KannaLife Sciences, Inc. stated, "We are very proud of our efforts to date in designing a rational and viable commercial development plan for a target therapeutic with a potentially new and exciting mechanism of action. We are greatly appreciative of the efforts put forth by the dedicated professionals and scientists at NIH-OTT who worked with us during the licensing process, and for helping to bring the exclusive licensing of the '507 Patent to a successful conclusion. We believe the initiatives put forth by President Obama and his administration regarding small business played a big role in providing KannaLife with the opportunity of competing in an equitable licensing arena."

About the NIH Office of Technology Transfer (NIH-OTT):

NIH-OTT manages the patenting and licensing of a wide range of inventions made by scientists working for the NIH and FDA intramural research programs as mandated by the Federal Technology Transfer Act.

Additional information about NIH-OTT can be found at http://www.ott.nih.gov.

About KannaLife Sciences, Inc.

KannaLife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.

Website: www.kannalife.com


'/>"/>
SOURCE KannaLife Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Stemtech Signs Exclusive Deal With Marinova For Fucoidan
4. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
5. Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.
6. Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe
7. Masimo Signs Pronto-7™ Distribution Deal with Henry Schein
8. MusclePharm Signs Pro Baseball Rookie Phenom Bryce Harper As Sponsored Athlete
9. Bacterin International Signs Its Third National GPO Contract with Novation
10. H. D. Smith Signs Three Year Prime Vendor Agreement with PharmacyGPO Buying Group
11. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2020)... ... , ... Special Learning, Inc. is the leading global provider of Autism and ... lives of people with autism and other special needs. , It has ... Special Learning will be providing some of the key components of a comprehensive ...
(Date:2/20/2020)... ... 20, 2020 , ... NJ Top Docs practice, The Rubino OB/GYN Group hosted ... on Thursday, January 16 at 12PM. The Rubino OB/GYN Group founder, Dr. Robert ... Members of the public and media were also in attendance. , The office space ...
(Date:2/20/2020)... ... February 20, 2020 , ... Enquire, a leading provider of cloud CRM, ... proud to announce G5 as a Silver Sponsor of Enquire Summit 2020, scheduled for ... return to Enquire Summit as a Silver Sponsor. This event truly empowers sales and ...
Breaking Medicine Technology:
(Date:2/26/2020)... ... February 26, 2020 , ... Nutricare’s PATCH bamboo ... where they'll be showcasing their pioneering line of compostable bamboo bandages while competing for ... at Expo West, and we were blown away by the support and interest in ...
(Date:2/21/2020)... ... February 21, 2020 , ... Representatives with ... a 10 percent grand opening discount 0n its anti-colic portable baby bottle blender. ... Osmay Gonzalez, spokesperson for Baby Blendy LLC, a member of the Juvenile Products ...
(Date:2/21/2020)... (PRWEB) , ... February 21, 2020 , ... ... providing nutrition and lifestyle solutions, has announced its third and final round of ... This Judging Period’s finalists are John Birr of Markdale, Ontario; Taiya Farrell of ...
(Date:2/19/2020)... , ... February 19, 2020 , ... ... with a grant of $10,000.00 from the Doug Flutie, Jr. Foundation for Autism. ... for students with autism. , The physical fitness program will include the hiring ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... the scope of regulations and requirements that currently govern medical device manufacturers under ... which extends until 25 May 2020. Major changes from the previous MDD include:, ...
Breaking Medicine News(10 mins):